BSE Live
Oct 03, 16:01Prev. Close
5710.70
Open Price
5788.45
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 03, 15:57Prev. Close
5710.00
Open Price
5759.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
5866.00 (45)
Profit & Loss account of Divis Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 5,291.17 | 4,803.82 | 3,828.74 | 4,095.22 | 3,797.51 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 21.29 | 41.92 | 28.52 | |
Revenue From Operations [Net] | 5,291.17 | 4,803.82 | 3,807.45 | 4,053.30 | 3,768.99 | |
Total Operating Revenues | 5,394.42 | 4,946.26 | 3,891.49 | 4,064.34 | 3,776.36 | |
Other Income | 189.63 | 155.63 | 113.44 | 74.89 | 97.44 | |
Total Revenue | 5,584.05 | 5,101.89 | 4,004.93 | 4,139.23 | 3,873.80 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 2,198.41 | 2,103.89 | 1,528.57 | 1,572.75 | 1,477.78 | |
Purchase Of Stock-In Trade | 16.11 | 25.92 | 2.16 | 2.07 | 0.93 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FGWIP And Stock In Trade | -105.98 | -304.59 | 3.33 | -40.82 | 25.37 | |
Employee Benefit Expenses | 621.05 | 542.27 | 456.06 | 499.90 | 361.19 | |
Finance Costs | 6.10 | 3.50 | 1.33 | 2.25 | 3.78 | |
Depreciation And Amortisation Expenses | 186.24 | 168.90 | 142.49 | 123.33 | 118.18 | |
Other Expenses | 842.66 | 706.93 | 639.66 | 584.41 | 493.72 | |
Total Expenses | 3,764.59 | 3,246.82 | 2,773.60 | 2,743.89 | 2,480.96 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1,819.46 | 1,855.07 | 1,231.33 | 1,395.34 | 1,392.84 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 1,819.46 | 1,855.07 | 1,231.33 | 1,395.34 | 1,392.84 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 392.79 | 475.51 | 289.83 | 285.23 | 284.23 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | 50.13 | 26.82 | 64.49 | 49.69 | -17.17 | |
Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 442.92 | 502.33 | 354.32 | 334.92 | 267.06 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 1,376.54 | 1,352.74 | 877.01 | 1,060.42 | 1,125.78 | |
Profit/Loss From Continuing Operations | 1,376.54 | 1,352.74 | 877.01 | 1,060.42 | 1,125.78 | |
Profit/Loss For The Period | 1,376.54 | 1,352.74 | 877.01 | 1,060.42 | 1,125.78 | |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Consolidated Profit/Loss After MI And Associates | 1,376.54 | 1,352.74 | 877.01 | 1,060.42 | 1,125.78 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 52.00 | 51.00 | 33.00 | 40.00 | 42.00 | |
Diluted EPS (Rs.) | 52.00 | 51.00 | 33.00 | 40.00 | 42.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 1,024.12 | 265.47 | 319.50 | 0.00 | 639.02 | |
Tax On Dividend | 0.00 | 54.57 | 0.00 | 0.00 | 100.00 |
10.09.2025
Reduce Divis Laboratories; target of Rs 5400: Geojit Financial Services
07.08.2025
Accumulate Divis Laboratories; target of Rs 6550: Prabhudas Lilladher
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
23.05.2025
Accumulate Divis Laboratories; target of Rs 7518: Deven Choksey
07.08.2025
Divis Labs Standalone June 2025 Net Sales at Rs 2,357.00 crore, up 14.25% Y-o-Y
19.05.2025
Divis Labs Consolidated March 2025 Net Sales at Rs 2,585.00 crore, up 12.24% Y-o-Y
19.05.2025
Divis Labs Standalone March 2025 Net Sales at Rs 2,536.00 crore, up 12.26% Y-o-Y
03.02.2025
Divis Labs Consolidated December 2024 Net Sales at Rs 2,319.00 crore, up 25.01% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill